Axsome Therapeutics, Inc. AXSM

Latest FY: 2025 Healthcare Biotechnology
Market Price $208.47
Market Cap $10.73B
P/E Ratio N/A
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑65.5% YoY
$638.50M
3-Yr CAGR: 133.7%
Net Income ↑36.2% YoY
-$183.17M
Net Margin: -28.7%
Free Cash Flow ↑27.0% YoY
-$93.89M
FCF Yield: -0.88%
EPS (Diluted) ↑38.6% YoY
$-3.68
Basic: $-3.68
Return on Equity Efficiency
-207.5%
ROA: -26.6%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (AXSM)

All monetary values in millions ($M)
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Div / Sh Div Yield Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $-27.2M $-1.42 0.00% $-21.3M $-21.4M
FY 2017 $-28.9M -6.4% $-1.27 +10.6% 0.00% $-26.5M $-26.5M -23.8%
FY 2018 $-31.0M -7.0% $-1.15 +9.4% 0.00% $-30.1M $-30.1M -13.6%
FY 2019 $-68.3M -120.7% $-2.01 -74.8% 0.00% $-46.4M $-46.4M -54.2%
FY 2020 $-102.9M -50.6% $-2.77 -37.8% 0.00% $-78.5M $-78.5M -69.2%
FY 2021 $-130.4M -26.7% $-3.47 -25.3% 0.00% $-108.2M $-108.5M -38.3%
FY 2022 $50.0M $42.7M $-187.1M -43.5% $-4.60 -32.6% 0.00% $-116.5M $-117.2M -8.0%
FY 2023 $270.6M +440.8% $244.5M $-239.2M -27.8% $-5.27 -14.6% 0.00% $-145.1M $-145.7M -24.3%
FY 2024 $385.7M +42.5% $352.4M $-287.2M -20.1% $-5.99 -13.7% 0.00% $-128.4M $-128.7M +11.7%
FY 2025 $638.5M +65.5% $591.0M $-183.2M +36.2% $-3.68 +38.6% 0.00% $-93.4M $-93.9M +27.0%
$

Valuation

Market Price $208.47
Market Cap $10.73B
Enterprise Value $10.59B
P/E Ratio N/A
P/B Ratio 121.50
FCF Yield -0.88%
Dividend Yield N/A
Shares Outstanding 51,459,800
%

Profitability & Margins

Gross Margin 92.56%
Operating Margin -26.12%
Net Margin -28.69%
Return on Equity (ROE) -207.46%
Return on Assets (ROA) -26.55%
Asset Turnover 0.93x
Revenue 3-Yr CAGR 133.68%
🛡️

Financial Health & Liquidity

Current Ratio 1.55
Cash Ratio 0.85
Debt / Equity 2.126
Debt / Assets 0.272
Cash & Equivalents $322.93M
Total Debt $187.75M
Book Value / Share $1.72
💧

Cash Flow Efficiency

Operating Cash Flow -$93.41M
Capital Expenditures (CapEx) $480.00K
Free Cash Flow -$93.89M
OCF / Revenue -14.63%
FCF / Revenue -14.70%
FCF 3-Yr CAGR N/A
🏷️

Per Share Metrics

EPS (Diluted) $-3.68
EPS (Basic) $-3.68
Dividends / Share N/A
Book Value / Share $1.72
EPS YoY Growth 38.56%
🏛️

Balance Sheet (FY 2025)

Total Assets $689.80M
Total Liabilities $601.51M
Stockholders' Equity $88.30M
Current Assets $588.99M
Current Liabilities $378.84M